-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22

Benzinga·02/06/2026 11:36:56
Listen to the news
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.